Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease

Patent metadata

Field	Value
Publication number	US-10087489-B2
Application number	US-201615276131-A
Country	US
Kind code	B2
Filing date	Sep 26, 2016
Priority date	Dec 20, 2010
Publication date	Oct 2, 2018
Grant date	Oct 2, 2018

Abstract

Genetic biomarkers for left side colon cancer (LCC) (such as expression levels of an RNA transcript or expression product of NOX4, MMP3, or a combination) and right side colon cancer (RCC) (such as expression levels of an RNA transcript or expression product of CDCX2, FAM69A, or a combination), are disclosed. Methods for using the biomarkers in providing a prognosis of relapse-free survival probability in patients having LCC or RCC are also presented. Prognostic panels using gene expression values of the biomarkers are also presented. Computer implemented methods employing the biomarkers, and as well as for determining relapse-free survival probability in a patient having RCC or LCC are provided. A genetic method for classifying a colon cancer tissue as a RCC or as a LCC is also disclosed.

First claim

What is claimed is:

1. A panel of probes for indicating a 5-year right-side colon cancer (RCC) relapse probability of RCC in a post-surgery human RCC patient, said panel of probes consisting of detectably labeled single-stranded polynucleotides complementary to mRNA or cDNA of two or more genes selected from the group consisting of:
CDX2, FAM69A, FAM84A, ITPRIP, ITGA3, RAB3B, SMAD3, PCSKS, and MMP28.

2. A panel of probes for indicating a 5-year right-side colon cancer (RCC) relapse probability of RCC in a post-surgery human RCC patient, said panel of probes consisting of detectably labeled single-stranded polynucleotides complementary to mRNA or cDNA of two or more genes selected from the group consisting of:
CDX2, FAM69A, FAM84A, ITPRIP, ITGA3, RAB3B, SMAD3, PCSK5, MMP28,CDKN2B, GADD45A, and CCND1.

3. A panel of probes for indicating a 5-year RCC relapse probability of RCC in a post-surgery human RCC patient, said panel of probes consisting of detectably labeled single-stranded polynucleotides complementary to mRNA or cDNA of CDX2 and FAM69A.

4. The panel of probes of claim 1 , 2 or 3 , wherein the detectably labeled single-stranded polynucleotides are immobilized to a solid surface.

5. The panel of probes of claim 1 , 2 or 3 wherein the detectable label is a fluorescent label or a radiolabel.

6. The panel of probes of claim 4 , wherein the solid surface is nylon, plastic, silicon, or ceramic.

7. The panel of probes of claim 4 wherein the solid surface is a silicon wafer.

8. The panel of probes of claim 4 wherein the solid surface is a glass.

9. The panel of probes of claim 8 wherein the glass is a glass slide or a glass chip.

10. The panel of probes of claim 4 wherein the probes are fixed to the solid surface by a covalent bond.

Assignees

• Univ Notre Dame Du Lac
• The Univ Of Notre Dame

Inventors

• Buechler Steven
• Hummon Amanda B

Classifications

• G01N33/57535 Primary

  of the large intestine, e.g. colon, rectum or anus · CPC title

• G01N33/5758

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• G01N2800/54

  Determining the risk of relapse · CPC title

• G01N33/57484

  Physics · mapped topic

• C12Q1/686

  Polymerase chain reaction [PCR] · CPC title